Ginsenoside Rg1 Attenuates Oligomeric Aβ1-42-Induced Mitochondrial Dysfunction by Huang, Tianwen et al.
Ginsenoside Rg1 Attenuates Oligomeric Aβ1-42-Induced
Mitochondrial Dysfunction
Tianwen Huanga,b,#, Fang Fangc,#, Limin Chena, Yuangui Zhua,b, Jing Zhanga, Xiaochun
Chena,b,*, and Shirley Shidu Yanc,*
aDepartment of Neurology, Fujian Institute of Geriatrics, the Affiliated Union Hospital of Fujian
Medical University, Fuzhou, Fujian 350001, China
bCentre for Neurobiology of Fujian Medical University, Fuzhou, Fujian 350001, China
cDepartment of Pharmacology & Toxicology, School of Pharmacy, Higuchi Bioscience Center,
University of Kansas Lawrence, Kansas, KS 66047, USA
Abstract
Mitochondrial dysfunction is one of the major pathological changes seen in Alzheimer's disease
(AD). Amyloid beta-peptide (Aβ), a neurotoxic peptide, accumulates in the brain of AD subjects
and mediates mitochondrial and neuronal stress. Therefore, protecting mitochondrion from Aβ-
induced toxicity holds potential benefits for halting and treating and perhaps preventing AD. Here,
we report that administration of ginsenoside Rg1, a known neuroprotective drug, to primary
cultured cortical neurons, rescues Aβ-mediated mitochondrial dysfunction as shown by increases
in mitochondrial membrane potential, ATP levels, activity of cytochrome c oxidase (a key enzyme
associated with mitochondrial respiratory function), and decreases in cytochrome c release. The
protective effects of Rg1 on mitochondrial dysfunction correlate to neuronal injury in the presence
of Aβ. This finding suggests that ginsenoside Rg1 may attenuate Aβ-induced neuronal death
through the suppression of intracellular mitochondrial oxidative stress and may rescue neurons in
AD.
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INTRODUCTION
Alzheimer's disease (AD) is the most common form of dementia and affects millions of
people worldwide. However, mechanisms of AD remain unclear. One dominant theory in
the field since 1992, the amyloid hypothesis, suspects that Aβ42 shifts from fibrils to
protofibrils to oligomers to perhaps dimers [1–5]. A large body of recent evidence points to
the overproduction and accumulation of Aβ (particularly oligomeric Aβ1-42) as a trigger of
the pathological cascade in AD.
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Mitochondrial dysfunction is an early pathological feature of AD. It is known that activities
of several mitochondrial enzymes are altered in AD [6, 7]. Impairments in energy
metabolism and increased oxidative stress occur in AD brain. Recent studies show a
significant Aβ accumulation in mitochondria of AD brain and transgenic AD mouse models
[8–13]. Aβ-rich mitochondria have deficits in mitochondrial function such as impaired
respiratory function, decreased ATP levels, increased opening of the membrane permeability
transition pore (mPTP) and reactive oxygen free radicals (ROS), and impaired calcium
buffering capacity [7–9, 12, 14–16]. Furthermore, Aβ can directly intervene with
mitochondrial and neuronal function. For example, treatment of oligomeric Aβ causes
decreased mitochondrial membrane potential, decreased activity of cytochrome c oxidase
(CcO), and increased cytochrome c release, resulting in neuronal apoptosis [9]. These
studies indicate that Aβ-induced neural mitochondrial dysfunction plays an important role in
the pathogenesis of AD [17–20]. Therefore, the inhibition of Aβ-mediated neuronal
mitochondrial stress may have potential benefits for halting, treating and/or preventing AD.
Ginseng, on the other hand, has long been used to alleviate many ailments, particularly those
associated with aging and memory deterioration [21]. A representative constituent of
ginsenoside, Rg1 Fig. (1), may be a candidate neuroprotective agent for treating AD and in
fact, has been documented to produce antioxidant effects [22–27]. However, whether
ginsenoside Rg1 has any protective effect on Aβ-induced mitochondrial injury has not yet
been reported. In this study, we assessed the effects of ginsenoside, Rg1, on mitochondrial
function associated with neurotoxicity from oligomeric Aβ in primary cultured cortical
neurons. Our results clearly show that Rg1 treatment significantly improves mitochondrial
function contributing to decreased neuronal death.
MATERIALS AND METHODS
Materials
Ginsenoside Rg1 was obtained from the Department of Biochemistry, Norman Bethune
Medical College of Jilin University (Jilin, China) in the form of white powder-like crystals,
with a melting point of 194–195°C, a molecular weight of 800, general formula C42H72O14
Fig. (1), and a purity of over 98% as documented by reverse phase high-pressure liquid
chromatography (HPLC). Aβ1-42 was purchased from QCB (Quality Controlled
Biochemicals) (Hopkinton, MA, USA). Oligomeric Aβ1-42 peptide was prepared as
described previously, and characterized by atomic force microscopy [9]. Neurobasal
Medium, Trypsin-EDTA, L-glutamin, B27 Supplement, Fetal Bovine Serum (FBS) were
purchased from Gibco-BRL (Grand Island, NY, USA). POLY-LYSINE, Cytochrome c and
dichlorofluorescin diacetate (DCFH-DA) were obtained from Sigma Chemical Co. (St.
Louis, MO, USA). The caspase-3 Assay kit was obtained from Clontech Laboratories Inc,
(Mountain View, CA, USA) and Function ELISA Cytochrome c and Mitochondrial
Fractonation kits from Active Motif (Carlsbad, CA, USA). The Peroxide/Peroxidase Assay
Kit was from Molecular Probes, Inc. (Eugene, OR, USA), the JC-1 Mitochondrial
Membrance Potential Detection Kit from Cell Technology (Mountain View, CA, USA), the
ATP Bioluminescence Assay Kit HS II from Roche company (Indianapolis, IN, USA), and
the Apoptosis detection kit from Trevigen company (Gaithersburg, MD, USA).
Cortical Neuron Culture and Treatment
Cortical neurons from C57BL/6 mouse fetuses at embryonic days 15–16 (Fuzhou Animal
Center, Fuzhou, China) were prepared as described previously [7, 28]. All procedures
followed the ethical guidelines for investigations of experimental pain in conscious animals
and were approved by the Institutional Animal Care Committee of Fujian Medical
University. Following the above procedures, cultures typically contained more than 90%
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neurons as assessed by staining with an antibody against phosphorylated neurofilament (data
not shown). After 3 days in vitro, the cells were preincubated with Rg1 or other drugs for 24
h, and then co-incubated with Aβ1-42 (5 μM final concentration) for 48 h or other indicated
lengths of time.
Mitochondria Membrane Potential
Loss of mitochondrial membrane potential was determined using the JC-1 mitochondrial
transmembrane potential detection kit (Cell Technology, Inc.) according to the manufacturer
instructions. Briefly, neurons were treated with ginsenoside Rg1 and/or oligomeric Aβ1-42
for different time points. Neurons were then collected, suspended in 0.5mL 1× JC-1 reagent,
and incubated at 37°C in a 5% CO2 incubator for 15 minutes. The cells were then collected
by centrifugation and the pellet was washed with 2 ml assay buffer (1×) and resuspended in
0.3 ml Assay Buffer. One hundred μl cell suspension was transferred into a black 96-well
plate (triplicate for each sample). Red fluorescence (excitation 550 nm, emission 600 nm)
and green fluorescence (excitation 485 nm, emission 535 nm) were measured with a
fluorescence plate reader (BioTek Senergy HT, Vermont, USA). The ratio of red to green
fluorescence, an indicator for membrane potential, was determined. The ratio was decreased
in dead cells and in cells undergoing apoptosis in comparison with healthy cells.
ROS Measurement
The dichlorofluorescein (DCF) assay was used to measure the levels of ROS. The cell-
permeable dichlorofluorescein diacetate (DCFH-DA) crosses into the cytoplasm, where it is
de-esterified by cellular esterase resulting in DCFH. DCFH in turn is converted upon
oxidation to the highly fluorescent DCF. By measuring the fluorescence, we are able to
quantify the levels of ROS. After incubation with Aβ1-42 for varying lengths of time,
neurons were washed with PBS and incubated with 10 μM of nonfluorescent DCFH-DA for
30 min at 37 ° in the incubator with 5 % CO2. The measurements were performed on a
microplate fluorometer (BioTek Senergy HT, Vermont, USA) with λex 480 nm and λem
530 nm.
Intracellular production of H2O2 was fluorometrically determined according to the
manufacturer's instructions (Amplex Red, Molecular Probes). Cells plated on 96-well plates
were incubated with the fresh growth medium containing agents to be tested. Cultures were
exposed to a working solution containing 50 μM Amplex Red reagent and 0.1 U/ml
horseradish peroxidase (HRP) for 60 min. Fluorescence was measured with the excitation at
540 nm and the emission at 590 nm using a microplate fluorometer (BioTek Senergy HT,
Vermont, USA).
Measurement of Cytochrome c Oxidase (CcO) Activity
Complex IV activity was measured as described previously [7]. Briefly, neuronal cultures in
six-well plates were washed with ice-cold PBS, and cells were harvested, centrifuged, and
suspended in 50 μl of isolation buffer containing 250 mM sucrose, 20 mM HEPES, pH 7.2,
and 1 mM EDTA. Cell suspensions (containing ~3–4 mg of protein/ml) were added to a
cuvette containing 0.95 ml of 1× assay buffer (10 mM Tris-HCl, pH 7.0, and 120 mM KCl),
and the reaction volume was brought to 1.05 ml with 1× enzyme dilution buffer (10 mM
Tris-HCl, pH 7.0). The reaction was then started by the addition of 50 μl of ferrocytochrome
c substrate solution (0.22 mM) (from Sigma); the change in absorbance of cytochrome c at
550 nm was measured using a DU640 spectrophotometer (Beckman company, USA). The
reading was recorded every 5 sec during the first 3 minutes. Background levels were
measured without cell suspensions.
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ATP levels were determined using a luciferin/luciferase-based ATP assay kit (from Roche).
Briefly, neurons were treated with ginsenoside Rg1 and/or oligomeric Aβ1-42 for different
lengths of time. Neurons were harvested, centrifuged and diluted at a concentration of 1 ×
104 cells/ml. The same volume of cell lysis reagent was added to the samples and then
incubated them for 5 min at 25 °C. An appropriate volume of luciferase reagents were added
to the samples and the reading was recorded consecutively from 1 to 10 s with an interval of
1 s using a Microplate Luminometer MPL4, (Berthold, Pforzheim, Germany). The change
between different groups was compared.
Isolation of Mitochondria and Cytochrome c Release
The Mitochondrial Fractionation kit (from Active Motif, Inc.) was used to isolate
mitochondrial and cytosolic fractions from cells according to the manufacturer's
instructions. Briefly, primary cortical neurons were treated with ginsenoside Rg1 and/or
oligomeric Aβ1-42. The treated neurons were scraped and spun twice at 600 × g for 5
minutes. Ice-cold 1X cytosolic buffer was added and the cell pellet was resuspended and
incubated on ice for 15 minutes. Cells were homogenized and the lysate was spun twice at
800 × g for 20 minutes. The resultant supernatant contained the cytosol, including
mitochondria; the supernatant was spun at 10,000 × g for 20 minutes to pellet the
mitochondria. The mitochondrial pellet was washed and spun with 1X cytosolic buffer at
10,000 × g for 10 minutes, and then lysed by adding Complete Mitochondria Buffer
followed by incubation on ice for 15 minutes, the result of which was the Mitochondrial
fraction. At the same time, the supernatant was centrifuged at 16,000 × g for 25 minutes.
The centrifuged supernatant was the cytosolic fraction. The protein concentration was
measured by using a Bio-Rad protein assay.
After isolation of mitochondria and cytosolic fraction, the ELISA Cytochrome C kit (from
Active Motif, Inc.) was used to measure the level of cytochrome c according to the
manufacturer's instructions.
Assessment of Apoptosis
Apoptosis in cultured neurons was assessed by TUNEL assay under light microscopy.
Neurons grown on coverslips were washed and fixed in 3.7 % paraformaldehyde for 10 min
at 18–24°C and then post-fixed with 100 % alcohol for 20 min and washed in PBS for 10
min. The previously treated neurons were first covered with 50 μl of NeuroPore, incubated
for 25 minutes, and washed twice with PBS. Neurons were immersed in quenching solution
(3% hydrogen peroxide in Methanol) for 5 minutes, washed with PBS, and incubated in 1X
TdT Labeling Buffer for 5 minutes, and further covered with 50 μl of labeling reaction mix
followed by incubation at 37 °C for 1 hour in a humidity chamber. The labeling reaction was
stopped with 1X TdT Stop Buffer for 5 minutes. Finally, the treated neurons were carefully
washed, covered with 50 μl of Strep-HRP Solution for 10 minutes, and immersed in DAB
solution for 2 to 7 minutes. TUNEL-positive cells were counted in five fields per well and
averaged.
Caspase 3 Activity
Caspase-3 activity was measured according to the manufacturer's instructions (Clonteck
Laboratories). Briefly, primary cortical neurons were treated with ginsenoside Rg1 and/or
oligomeric Aβ1-42 for different lengths of time. The neurons were scraped and centrifuged at
400 × g for 5 min and then re-suspended in 50 μl chilled cell lysis buffer per 2 × 105cells
and incubated on ice for 10 min. Next, they were centrifuged again at maximum speed for
10 min at 4°C to precipitate cellular debris. The supernatants were transferred to new
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microcentrifuge tubes and 50 μl of 2X Reaction Buffer/ DTT Mix (10 μl of 1 M DTT stock
per 1 ml of 2X Reaction Buffer) was added. One μl of caspase-3 inhibitor (DEVD-CHO)
was added to 50 μl of one supernatant. Transferred supernatants were incubated at 37°C for
1 hr in a water bath. A parallel control reaction that did not contain conjugated substrate was
set up. Caspase 3 activity was assessed by reading excitation at 380-nm and emission at 460-
nm in a microplate fluorometer (BioTek Senergy HT, Vermont, USA).
Statistical Analysis
All numerical results were expressed as the mean± standard error of the mean (S.E.M.).
Data were analyzed by analysis of variance (ANOVA) followed by analysis of significance
(Tukey test) for multiple time points groups. The results from Rg1 or/and Abeta treated
groups for indicated time were compared using t test. Statistical analysis was carried out
using SPSS (version 11.0 for Windows).
RESULTS
Effect of Ginsenoside Rg1 on Oligomeric Aβ1-42-Induced Mitochondrial Function
To determine the effect of Rg1 on mitochondrial function and properties, we measured
mitochondrial membrane potential, ATP level, mitochondrial enzyme activity associated
with the respiratory chain, cytochrome c oxidase (CcO), and ROS levels in Aβ-treated
neurons as compared with Rg1 – treated neurons. First, we evaluated the loss of
mitochondrial membrane potential (ΔΨM) using JC-1 as an indicator. Upon Aβ exposure,
cortical neurons showed a statistically significant time-dependent decrease in ΔΨM when
compared to the control Fig. (2A). However, pre-treatment with varying doses of
ginsenoside Rg1 (2.5–10 μM) showed a dose-dependent increase in ΔΨM as compared to
neurons treated with Aβ alone for either 24h or 48h Fig. (2B). The ΔΨM in vehicle-treated
control or ginsenoside Rg1 groups was higher than that of the Aβ1-42 treatment for 24h or
48h.
Second, we measured ATP levels. As shown in Fig. (2C), ATP generation in neurons treated
with Aβ1-42 was time-dependent decreased when compared to the control group, particularly
at 12h, 24h or 48h. However, in neurons pre-incubated with ginsenoside Rg1 and then co-
incubated with A for 24h or 48h, the ATP levels were significantly increased compared with
that of Aβ1-42 group for 24h or 48h Fig. (2D). Decreases in ATP levels correlated with the
change in ΔΨM.
Third, we analyzed mitochondrial respiratory function by measuring CcO activity. The
mitochondrial respiratory chain is composed of five enzyme complexes, and of these CcO
(complex IV) is vital. Defects in CcO activity have been shown in early stage AD brains
from AD mouse models and Aβ-treated neurons [29–34]. Neurons treated with 5μM
oligomeric Aβ1-42 for 12h to 48h demonstrated significantly decreased CcO activity Fig.
(2E). Notably, Rg1 pre-treatment significantly increased CcO activity in a dose-dependent
manner as compared to cells treated with Aβ1-42 alone for 24h or 48h Fig. (2F).
Given that mitochondria are a major source for generation and accumulation of reactive
oxygen species (ROS) and that mitochondrial dysfunction causes an increase in radical
production, we next determined the effect of Rg1 on reactive oxygen species (ROS)
production. ROS and H2O2, two predominant oxygen radicals, were detected
simultaneously. ROS and H2O2 were significantly increased in neurons exposed to Aβ1-42
Fig. (3A, C), especially in the group incubated with Aβ1-42 for 24h or 48h as compared to
the control group. Cells that were pre-incubated with Rg1 exhibited significantly reduced
levels of ROS and H2O2 when insulted by Aβ Fig. (3B, D).
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Cytochrome c Release: the Effect of Ginsenoside Rg1 and Oligomeric Aβ1-42
In most apoptosis pathways, mitochondrial cytochrome c release is a key event in initiating
the cascade of reactions leading to apoptotic cell death [35]. Therefore, cytochrome c levels
in cytosolic and mitochondrial fraction were detected separately after the neurons were
treated with 5 μM oligomeric Aβ1-42 for different time points (3h, 6h, 12h, 24h or 48h).
Levels of cytochrome c in cytosolic fraction were increased in a time-dependent manner in
parallel with the Aβ1-42 incubation time Fig. (4A), especially at 24h or 48h, when compared
to the control group. Similarly, cytochrome c levels in mitochondrial fraction were
decreased. However, we found less cytochrome c protein in Rg1-treated neurons in the
cytosolic fraction than vehicle-treated neuron in the presence of Aβ Fig. (4B). Similarly,
cytochrome c levels in mitochondrial fractions were increased significantly in Rg1-treated
group in comparison with that of the group treated only with Aβ1-42. These results suggest
that ginsenoside Rg1 attenuates Aβ-induced cytochrome c release from mitochondria.
The Effect of Ginsenoside Rg1 on Aβ1-42 -Induced Neurotoxicity
To determine whether the protective effect of ginsenoside Rg1 on Aβ-induced mitochondrial
dysfunction correlates to neurotoxicity, we assessed changes in morphology, apoptosis and
caspase-3 activity. Neurons were pre-treated with varying doses of ginsenoside Rg1 for 24h
and co-incubated with or without oligomeric Aβ1-42 for 48h and then analyzed under light
microscopy Fig. (5A). Our results showed a normal dense and consistent neurite network
radiating from the cell bodies to the periphery Fig. (5A1). By contrast, Aβ1-42 –treated
neurons showed peripheral fragmentation, partial loss of disordered neurites Fig. (5A2),
while the deformed neurites showed improvement when cells were preincubated with 10μM
ginsenoside Rg1 for 24h Fig. (5A4). Neurons treated with 10μM ginsenoside Rg1 grew well
Fig. (5A3), suggesting no toxic effect of Rg1 on neuronal function and that ginsenoside Rg1
protects the neurons from Aβ1-42–-induced toxicity.
To further test the protective effect of gisenoside Rg1 on Aβ1-42, the TUNEL method was
used to detect apoptotic neurons treated with gisenoside Rg1 and/or Aβ1-42. Upon exposure
to Aβ1-42, cortical neurons showed a dose-dependent increase in the number of apoptotic
nuclei compared to vehicle-treated control neurons Fig. (5B). In agreement with
morphologic observations Fig. (5A), ginsenoside Rg1 treatment significantly diminished
oligomeric Aβ1-42-induced apoptosis Fig. (5C–D). Neurons treated with ginsenoside Rg1
alone grew similar to those in the control group, indicating that ginsenoside Rg1 at 10μM
concentration is not harmful to neurons.
Given that caspase-3 plays a major role in the apoptosis process in response to stress, [36,
37], we next measured caspase-3 activity. Neurons treated with Aβ 1-42 showed significantly
increased caspase-3 activity in a dose-dependent manner but not in Rg1-treated neurons Fig.
(6 A–B). These data indicate that ginsenoside Rg1 treatment attenuates Aβ1-42-induced
neuronal damage through decreased apoptosis and rescued caspase activity.
DISCUSSION
Mitochondrial oxidative stress has been well characterized as a hallmark of both AD and Aβ
toxicity [38, 39]. In the present study, Aβ 1-42 treatment resulted in dose-dependent changes
in caspase-3-like activity and TUNEL with the most-pronounced change at 5 μM in cortical
neurons. Our results are consistent with the published observation that Aβ1-42 insult results
in neurotoxicity.
Mitochondria function as “cellular power plants” because they generate most of the cellular
ATP, which is used as a source of chemical energy. These organelles produce ATP through
the coupling of oxidative phosphorylation with respiration. Mitochondrial dysfunction is
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present and decreases in several mitochondrial enzyme activities are present in AD,
including pyruvate dehydrogenase complex, ketoglutarate dehydrogenase complex, and CcO
Vmax activities [40]. The CcO defect, in particular, is central to mitochondrial dys-function
in AD. Reduced enzyme activity, especially the CcO defect, results in elevated ROS and
reduced ATP levels; such reduced activity may also encourage excessive mitochondrial
membrane potential depolarization, increase cytoplasmic cytochrome c, and elevate
caspase-3 activity, resulting in the apoptosis of neurons [41, 42].
Therefore, the inhibition of neuronal mitochondrial oxidative stress may hold potential
benefits for the treatment of AD. In the present study, we found that oligomeric Aβ1-42
reduced CcO activity, decreased ATP levels, mitochondrial membrane potential and
cytochrome c in mitochondria, in addition to increasing levels of ROS and H2O2 and cyto-
chrome c in cytosolic fractions of cortical neurons. Our observations are consistent with the
previous report on deleterious effects of Aβ on mitochondrial function. Intriguingly, the
addition of Rg1 to neurons in the presence of Aβ significantly attenuates compromised
mitochondrial function, resulting in rescued neuronal function.
Release of cytochrome c and loss of membrane potential are key events in mitochondrial
apoptosis. In the current study, we showed that Rg1 protects neurons from Aβ1-42-induced
apoptosis, and that ginsenoside Rg1 reduced cyto-chrome c release from mitochondria to
cytosolic fraction that was induced by Aβ1-42. Ginsenoside Rg1 also attenuated the loss of
membrane potential. These findings suggest that ginsenoside Rg1 attenuates Aβ-induced
impairment of mitochondrial function.
Mitochondria are also major generators of ATP and reactive oxygen species (ROS) in cells
and tissues. To confirm the protective effect of ginsenoside Rg1, we analyzed levels of ROS,
H2O2 and ATP, and found that ginsenoside Rg1 attenuated the increase of ROS and H2O2,
and also attenuated the decreased ATP induced by oligomeric Aβ1-42. Changes in ATP
levels, accumulation of ROS, and impaired mitochondrial membrane potential are related to
the mitochondrial electron transport chain (ETC).
The CcO defect is central in AD mitochondria among the several mitochondrial enzyme
activities in the ETC. CcO reduction occurs at all stages of AD, including mild cognitive
impairment (MCI) [33]. Interestingly, we found ginsenoside Rg1 partly protected CcO from
the effects of oligomeric Aβ1-42 treatment. Therefore, we conclude that ginsenoside Rg1 can
preserve the ETC by protecting CcO, thereby promoting ATP generation, decreasing ROS
generation/accumulation, and eventually increasing mitochondria membrane potential and
reducing cytochrome c release from mitochondria.
Given that the CcO enzyme complex contains 13 protein subunits and we know that ten are
encoded by nuclear and three by mtDNA genes [43, 44], further investigation is needed to
elucidate whether ginsenoside Rg1 improves CcO activity through its protein subunits or
mtDNA [45]. Alternatively, CcO activity may be improved if ginsenoside Rg1 protects the
mitochondrial function in other pathways, such as through anti-oxidant mechanisms. The
detailed mechanisms underlying the ginsenoside Rg1-mediated pathways also require
further investigation.
Currently, there are several drug candidates in the pipeline, directly targeting the underlying
mechanisms of AD. Among the investigative therapies, mitochondria and anti-oxidant
therapeutic strategies have shown promise [46]. Previous studies have demonstrated
ginsenoside Rg1 has effective anti-amnesic, anti-aging and anti-oxidant effects [21, 47], but
it is unclear whether Rg1 has a protective effect on Aβ-impaired mitochondrial dysfunction.
The present studies provide the evidence of a beneficial effect of Rg1 on Aβ-induced
mitochondrial toxicity.
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In summary, our findings suggest that mitochondria are key players in Aβ-induced neuronal
damage in the pathogenesis of AD. The present study demonstrates that ginsenoside Rg1,
one of the main components of ginseng, has a protective effect in the maintenance of
mitochondrial function in addition to neuronal protection. In view of the significance of
mitochondria-mediated cell deaths including apoptosis and necrosis and the protective effect
of Rg1 on Aβ-induced mitochondrial damage including cytochrome c release, which will
trigger mitochondria-involved apoptosis, the present studies suggest that the protective
effects of Rg1 on mitochondrial function contribute, at least in part, to Aβ-insulted neuronal
damage. The detailed cause-effects of Rg1 on Aβ-induced mitochondrial and neuronal
dysfunction require further investigation. Our results provide a piece of telling evidence that
this ancient herb may indeed hold potential benefit for halting and treating age-related
diseases including AD.
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Fig. (1). Structure of ginsenside Rg1
Molecular formula: C42H72O14. Molecular weight of 800.
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Fig. (2). The effects of ginsenoside Rg1 on Aβ-induced mitochondrial abnormalities
Neurons were pretreated with ginsenoside Rg1 at 2.5–10 μM for 24 h, then exposed to
Aβ1-42 at 5.0 μM for the indicated time points. Levels of mitochondrial membrane potential
(Panels A and B), ATP (Panels C and D), and cyto-chrome c oxidase (CcO, Panels E and F)
were measured. NS: non significance. N = 3–5 per group of cells. Studies were repeated four
times and data were shown as mean ± SEM.
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Fig. (3). The effect of ginsenoside Rg1 on ROS generation
Neurons treated with Aβ1-42 (5.0 μM) at the indicated time points showed an increase in
DCF fluorescence intensity (an indicator of ROS generation (Panel A) and H2O2 production
(Panel C). Ginsenoside Rg1 treatment at the indicated concentration abolished oligomeric
Aβ1-42-induced ROS generation and H2O2 production (Panels B and D). NS: non
significance. N = 3–5 per group of cells. Data were expressed as mean ± SEM. Studies were
repeated at least three times.
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Fig. (4). The effect of ginsenoside Rg1 on Aβ-induced the release of mitochondrial cytochrome c
Neurons were treated with oligomeric Aβ1-42 (5 μM) alone (Panel A) or plus ginsenoside
Rg1 (Panel B). Levels of cytochrome c in the cytosolic fraction or mitochondrial fractions
were determined by ELISA. Ginsenoside Rg1 attenuated mitochondrial cytochrome c
releasing to cytosolic fraction in neurons induced by oligomeric Aβ1-42 at 5μM for 48 hr
(Panel B). * and # P <0.001 vs. Aβ treatment in mitochondrial fraction and cytosolic
fraction, respectively. Data were determined from four experiments.
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Fig. (5). The effect of ginsenoside Rg1 on Aβ1-42 -induced neurotoxicity
Cortical neurons were incubated in the absence (Panel A1, A3) or in the presence of 5uM
oligomeric Aβ1-42 for 48h (Panel A2 and A4) or in the presence of 10uM ginsenoside Rg1
(A3) alone, respectively. The cells (Panel A4) were preincubated with 10uM ginsenoside
Rg1 for 24h and co-incubated with 5uM oligomeric Aβ1-42 for 48h. Panel B–D. The effect
of ginsenoside Rg1 on apoptosis. The percentage of TUNEL-positive neurons was increased
in neurons treated with oligomeric Aβ1-42 at 5μM for 48 hours in a dose-dependent manner
(B). The ginsenoside Rg1 treatment decreased the Aβ-induced TUNEL-positive neurons in a
reverse dose-dependent manner (C). N = 3–5 per group of cells. Studies were repeated five
times and data were expressed as mean ± SEM. D. The representative images showed
TUNEL-positive apoptotic cells.
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Effect of Rg1 on oligomeric Aβ1-42-induced neuronal caspase-3 activity. Oligomeric Aβ1-42
at the indicated doses increased caspase-3-like activity (A), whereas ginsenoside Rg1 largely
attenuated that increase (Panel B). Data were determined from five experiments and
expressed as mean ± SEM.
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